生命科学资讯

Decoding early synaptic failure in Alzheimer’s disease through multiomic analysis - Illumina

Illumina’s AI-Driven Data Vision Is Expanding — Will Multiomics Integration Unlock a Transformational Edge? - Smartkarma

Agilent Technologies (A) Valuation Check After FDA Expansion Of Keytruda Companion Diagnostic - simplywall.st

Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating - TipRanks

The future of global food security may depend on quality agrigenomics software - Illumina

People On The Move: Appointments At Sanofi, Lonza, SkinBioTherapeutics - Citeline News & Insights

Agilent Technologies (A) Stock Analysis: Unpacking A 34.86% Potential Upside For Investors - DirectorsTalk Interviews

Zymedi describes new KARS1 inhibitors for cancer metastasis

Adlai Nortye discloses new PROTACs for STAT protein degradation

Beijing Tide Pharmaceutical reports ATR kinase inhibitors

Sichuan Kelun-Biotech Biopharmaceutical discovers new ADCs targeting CDH3

Insilico Medicine presents new KIF18A inhibitors

M&G PLC Buys 47,644 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat

Vanguard Group Inc. Has $16.42 Billion Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook

Eagle Rock Investment Company LLC Buys 8,246 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat

Waters Corporation (NYSE:WAT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

SETDB1 enables development beyond cleavage stages by extinguishing the MERVL-driven two-cell totipotency transcriptional program in the mouse embryo